1672.HK
ASCLETIS-B
HK$14.23
+1.43%
2026-05-29
About ASCLETIS-B
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Key Fundamentals
Forward P/E
-50.82
EPS (TTM)
HK$-0.43
ROE
-18.5%
Revenue Growth (YoY)
-26.2%
Profit Margin
0.0%
Debt/Equity
0.27
Price/Book
6.31
Beta
0.47
Market Cap
HK$15.02B
Avg Volume (10D)
2.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$19.86
60D Low
HK$12.68
Avg Volume
2.3M
Latest Close
HK$14.23
Get breakout alerts for 1672.HK
Sign up for Breakout Scanner to receive daily notifications when 1672.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ASCLETIS-B (1672.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1672.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1672.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.